Short Term Trading - Weekend Lounge: 30 Jun - 2 Jul, page-57

STTCOMP MEB, FA Long

Share price: 36c
Market Cap: $50M

Medibio (ASX: MEB), is a medical technology company that has developed an objective test to assist in the diagnosis of depression, chronic stress and other mental health disorders. This tip is base on the imminent release of Johns Hopkins University results.........which are only around 6 months overdue!! But the study is now completed and all data has been collected.

Medibio’s depression diagnostic is being validated in clinical studies undertaken by Johns Hopkins University School of Medicine and The University of Ottawa, among others. The clinical trials will support Medibio’s application to become the first FDA approved, objective, and evidence based approach to the diagnosis of mental health disorders. Medibio’s technology also provides an objective method for the assessment of stress and mental well being that can be translated to the workplace stress/well being market, wearable technology and App market.

The company recently appointed Michael Phelps to the board........

The next few slides are just some highlights for their products, past results and timelines etc............